Overview

Transverse Abdominus Plane Block Study

Status:
Not yet recruiting
Trial end date:
2024-02-12
Target enrollment:
0
Participant gender:
All
Summary
Study the effect of laparoscopic guided TAP block on opioid consumption and associated costs using a mixture of dexmedetomidine, dexamethasone, and ropivacaine versus Liposomal bupivacaine (Exparel®) in patients who undergo elective minimally invasive colorectal surgery.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Colorado, Denver
Treatments:
BB 1101
Bupivacaine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Dexmedetomidine
Ropivacaine
Criteria
Inclusion Criteria:

- provision to sign and date the consent form.

- stated willingness to comply with all study procedures and be available for the
duration of the study.

- Male and female patients aged 18 and older

- Benign or malignant colorectal disease undergoing laparoscopic, robotic, or a "hybrid"
(minimally invasive dissection with a 6-8 cm incision to complete the surgery)
colorectal resection with or without an ostomy

Exclusion Criteria:

- Pregnant or breastfeeding patients

- Medical conditions that may interfere with the use of the study medications (e.g.,
drug allergy),

- Patients with opioid dependence defined as chronic opioid use more than 3 times per
week preoperatively

- Incarcerated individuals

- Age less than 18 years-old

- Urgent/emergent operations as defined by need for operation within 24 hours

- Other conditions or general disability or infirmity that in the opinion of the
investigator precludes further participation in the study.

- Enrollment in another concurrent study with use of investigational drugs